RxDoctor Payments Data

Aaron Napier

Family · Manchester, KYNPI 1649926866

Payments from drug & device makers

$2,849in general payments, 2019–2025

Across 176 payments — averaging $16.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$571
  • AstraZeneca$447
  • AbbVie$428
  • Lilly USA, LLC$386
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$198
  • Ardelyx, Inc.$172
  • plus $648 from 14 others

What the payments were for

  • Food & beverage$2,849100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,849 in reported general payments places this provider in the 85th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide65$62,999
Breztri AerosphereBudesonide/Glycopyr/Formoterol51$37,802
MounjaroTirzepatide31$32,740
EliquisApixaban46$31,253
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$16,015
JanuviaSitagliptin Phosphate12$13,414
FarxigaDapagliflozin Propanediol16$12,315
JardianceEmpagliflozin18$10,772
LinzessLinaclotide15$8,901
Humalog Kwikpen U-200Insulin Lispro15$8,231
XareltoRivaroxaban12$7,835
Ondansetron Hcl36$7,277
MyrbetriqMirabegron12$5,151
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$5,022
Albuterol Sulfate HfaAlbuterol Sulfate174$4,847

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$571$62,99965 claims
AstraZenecaBreztri Aerosphere, Farxiga$447$50,11767 claims
Lilly USA, LLCMounjaro$386$32,74031 claims
GSKTrelegy Ellipta$59$16,01526 claims
MerckJanuvia$74$13,41412 claims
Boehringer IngelheimJardiance$30$10,77218 claims
AbbVieLinzess$428$8,90115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,374 family providers in Kentucky.

Other family in Manchester

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →